FLT3 and acute myeloid leukemia: Until international standards are established, CLSG/GCEL will strive to standardize national FLT3-ITD allelic burden testing and reporting to ensure that all Canadian AML patients receive the same care and to support the collection of consistent data upon which to base future recommendations.